DBV Files Peanut Patch BLA, Flags Going-Concern Doubt

The Tip Desk · November 9, 2026 · 3 min read

Cash stood at $165.7 million as of September 30, 2026, funding into the third quarter of 2027 after $50.0 million of ATM ADS sales.

DBV Technologies (DBVT), a late-stage specialty biopharmaceutical company, submitted a Biologics License Application to the U.S. Food and Drug Administration on September 29, 2026 for the VIASKIN® Peanut Patch in children aged 4 through 7 years and requested Priority Review, after saying in July that the filing was anticipated in the third quarter.

Chief Executive Officer Daniel Tassé said the quarter marked a step in the company’s shift from a clinical-stage organization toward a commercial one, with the 4-through-7 BLA now filed and a planned BLA for toddlers aged 1 through 3 years. The BLA is supported by the Phase 3 VITESSE trial, which enrolled 654 children.

The company recorded $4.7 million of BLA filing fees in the third quarter. Research and development expenses were $47.0 million, compared with $28.6 million in the year-ago quarter.

Sales and marketing expenses were $5.3 million as the U.S. commercial organization expanded and launch infrastructure advanced, including distribution and specialty pharmacy selection. General and administrative expenses were $14.0 million as corporate infrastructure scaled across Medical Affairs, Sales, Market Access, Marketing, Account Management, and Pharmacovigilance.

Operating income was $1.6 million, consisting of Research Tax Credit, as activities continued to shift from eligible research toward commercial readiness. Net loss was $64.5 million, or $0.14 a share, compared with $33.2 million, or $0.24 a share, a year earlier.

Cash and cash equivalents were $165.7 million as of September 30, 2026, after $50.0 million of gross proceeds from ADS sales under the company’s $150 million ATM program, which it also refreshed. The company said that cash funds operations into the third quarter of 2027.

Management updated operating and liquidity forecasts after the BLA submission to reflect the potential regulatory review pathway and the timing of related clinical, regulatory, manufacturing and commercial-readiness activities. The company said existing cash is not expected to be sufficient to fund operations for at least twelve months from the date of issuance of the financial statements, and that substantial doubt exists about its ability to continue as a going concern within twelve months. It said it will require additional capital and is evaluating ATM sales, equity transactions, warrant exercises and other financing.

Net cash used in operating and investing activities was $159.4 million for the nine months ended September 30, 2026, compared with $86.7 million a year earlier.

DBV said it has held discussions with the FDA on a timely review of the toddler BLA following the 4-through-7 filing, including a potential rolling submission, with the same review team handling both dossiers. The company expects to submit the toddler BLA in 2027 and will update investors once those discussions are finalized.

Manufacturing work continued with Fareva Amboise after the April 2026 FDA Warning Letter. The company said Fareva has responded to the FDA on regulatory timelines and provided monthly updates, and that a target date for the Pre-Approval Inspection was included in the BLA, falling after the date Fareva expects to complete remediation.

The company said it expects FDA’s determination in the fourth quarter of 2026 on whether the 4-through-7 BLA is sufficiently complete to begin substantive review, including whether Priority Review is granted.